Is Thrombocytosis Cancer?
Thrombocytosis itself is not cancer, but it can be either a sign of an underlying cancer (reactive thrombocytosis) or, less commonly, a manifestation of a blood cancer called essential thrombocythemia (ET), which is a myeloproliferative neoplasm.
Understanding the Two Types of Thrombocytosis
Thrombocytosis (elevated platelet count) falls into two distinct categories:
1. Reactive (Secondary) Thrombocytosis - NOT Cancer
This is the most common form where platelets are elevated in response to:
- Iron deficiency
- Infection or inflammation
- Surgery or splenectomy
- Underlying solid tumors (lung, colorectal, ovarian, etc.)
- Connective tissue disease
The elevated platelets here are a reaction to another condition, not a cancer themselves 1.
2. Clonal (Primary) Thrombocytosis - IS a Blood Cancer
Essential thrombocythemia (ET) is a Philadelphia-negative myeloproliferative neoplasm—a type of blood cancer where bone marrow produces too many platelets due to clonal proliferation 2, 1.
When Thrombocytosis Signals Underlying Solid Cancer
Thrombocytosis serves as an important risk marker for occult malignancy:
- In men: 11.6% with thrombocytosis (platelets >400 × 10⁹/L) are diagnosed with cancer within 1 year 3
- In women: 6.2% with thrombocytosis develop cancer within 1 year 3
- With persistent elevation (second raised count within 6 months): Risk increases to 18.1% in men and 10.1% in women 3
Most commonly associated cancers:
- Lung cancer
- Colorectal cancer
- Ovarian cancer
- Gastric/esophageal cancer
Notably, one-third of patients with thrombocytosis and lung or colorectal cancer had no other symptoms suggesting malignancy 3.
Distinguishing Essential Thrombocythemia (The Blood Cancer)
ET diagnosis requires meeting ALL four WHO criteria 1:
- Sustained platelet count ≥450 × 10⁹/L
- Bone marrow biopsy showing proliferation of megakaryocytic lineage with enlarged, mature megakaryocytes
- Exclusion of other conditions: Not meeting criteria for polycythemia vera, primary myelofibrosis, chronic myeloid leukemia, myelodysplastic syndrome, or other myeloid neoplasms
- Clonal marker present (JAK2V617F mutation in ~60%, CALR mutation in ~25%, MPL mutation in ~5%) OR absence of evidence for reactive thrombocytosis
Key Clinical Features of ET:
- Median survival approaches or exceeds 20 years 2
- Risk of thrombotic complications (major concern)
- Risk of hemorrhage with extreme thrombocytosis (≥1,500 × 10⁹/L) due to acquired von Willebrand disease 2
- <1% leukemic transformation rate at 10 years 4
- Potential progression to myelofibrosis
Clinical Approach Algorithm
When encountering thrombocytosis (platelets >400 × 10⁹/L):
- Repeat platelet count to confirm persistence
- Assess for reactive causes:
- Iron studies (iron deficiency is common)
- Inflammatory markers (CRP, ESR)
- Recent surgery or infection
- Splenectomy history
- Screen for occult malignancy, especially if:
- Consider hematology referral if:
- No reactive cause identified
- Persistent unexplained thrombocytosis
- Concern for myeloproliferative neoplasm
- Need for bone marrow biopsy and JAK2/CALR/MPL mutation testing
Prognostic Implications
Thrombocytosis in known cancer patients indicates worse outcomes:
- Associated with decreased 5-year overall survival (OR=2.70) 6
- Correlates with advanced tumor stage (OR=2.14 for stage III/IV disease) 6
- Linked to increased metastatic potential through platelet-tumor cell interactions 7
- Higher risk of thrombotic complications 8
Critical Distinction
The answer depends entirely on the underlying cause: Thrombocytosis as a laboratory finding is not inherently cancer. However, it can represent either a clonal blood cancer (essential thrombocythemia) or serve as a marker for underlying solid malignancy. The diagnostic workup must differentiate between these possibilities using WHO criteria, bone marrow examination, molecular testing, and exclusion of reactive causes 1.